UA77654C2 - Compressed tablet of linezolide - Google Patents

Compressed tablet of linezolide Download PDF

Info

Publication number: UA77654C2
Authority: UA; Ukraine
Prior art keywords: linezolid; hydroxypropyl cellulose; magnesium stearate; cellulose; microcrystalline cellulose
Prior art date: 2000-03-22

Application number

UA2002108322A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Upjohn Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-22

Filing date

2001-03-15

Publication date

2007-01-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22703542&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA77654(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-03-15 Application filed by Upjohn Co filed Critical Upjohn Co

2007-01-15 Publication of UA77654C2 publication Critical patent/UA77654C2/uk

Links

239000007891 compressed tablet Substances 0.000 title claims abstract description 6
TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 title claims description 48
229960003907 linezolid Drugs 0.000 title claims description 48
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 46
239000003826 tablet Substances 0.000 claims description 46
229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 40
239000001863 hydroxypropyl cellulose Substances 0.000 claims description 40
235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 40
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 37
229940016286 microcrystalline cellulose Drugs 0.000 claims description 37
239000008108 microcrystalline cellulose Substances 0.000 claims description 37
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 37
229920002261 Corn starch Polymers 0.000 claims description 25
239000008120 corn starch Substances 0.000 claims description 25
239000008109 sodium starch glycolate Substances 0.000 claims description 25
229940079832 sodium starch glycolate Drugs 0.000 claims description 25
229920003109 sodium starch glycolate Polymers 0.000 claims description 25
235000019359 magnesium stearate Nutrition 0.000 claims description 23
238000000034 method Methods 0.000 claims description 15
239000004203 carnauba wax Substances 0.000 claims description 10
235000013869 carnauba wax Nutrition 0.000 claims description 10
238000009501 film coating Methods 0.000 claims description 8
239000007888 film coating Substances 0.000 claims description 8
230000036765 blood level Effects 0.000 claims description 4
238000001990 intravenous administration Methods 0.000 claims description 4
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims 1
229920002678 cellulose Polymers 0.000 claims 1
239000001913 cellulose Substances 0.000 claims 1
235000010980 cellulose Nutrition 0.000 claims 1
229940020914 linezolid 600 mg Drugs 0.000 claims 1
IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 abstract description 19
230000000844 anti-bacterial effect Effects 0.000 abstract description 17
229940079593 drug Drugs 0.000 abstract description 3
239000003814 drug Substances 0.000 abstract description 3
239000003795 chemical substances by application Substances 0.000 abstract description 2
239000000203 mixture Substances 0.000 description 30
239000000243 solution Substances 0.000 description 20
238000000576 coating method Methods 0.000 description 17
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
239000002904 solvent Substances 0.000 description 15
239000011248 coating agent Substances 0.000 description 13
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 10
239000008187 granular material Substances 0.000 description 10
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 8
235000021355 Stearic acid Nutrition 0.000 description 8
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 8
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 8
239000008213 purified water Substances 0.000 description 8
239000008117 stearic acid Substances 0.000 description 8
150000001875 compounds Chemical class 0.000 description 7
238000003756 stirring Methods 0.000 description 7
239000000126 substance Substances 0.000 description 7
239000000725 suspension Substances 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
229920002472 Starch Polymers 0.000 description 6
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
239000007787 solid Substances 0.000 description 6
229940032147 starch Drugs 0.000 description 6
239000008107 starch Substances 0.000 description 6
235000019698 starch Nutrition 0.000 description 6
239000011230 binding agent Substances 0.000 description 5
239000008280 blood Substances 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000013078 crystal Substances 0.000 description 5
239000007884 disintegrant Substances 0.000 description 5
239000004615 ingredient Substances 0.000 description 5
239000000314 lubricant Substances 0.000 description 5
238000002156 mixing Methods 0.000 description 5
239000000843 powder Substances 0.000 description 5
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
229920002785 Croscarmellose sodium Polymers 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
125000000217 alkyl group Chemical group 0.000 description 4
229960001681 croscarmellose sodium Drugs 0.000 description 4
229960000913 crospovidone Drugs 0.000 description 4
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 4
238000010586 diagram Methods 0.000 description 4
238000009792 diffusion process Methods 0.000 description 4
238000005516 engineering process Methods 0.000 description 4
229950008631 eperezolid Drugs 0.000 description 4
238000005469 granulation Methods 0.000 description 4
230000003179 granulation Effects 0.000 description 4
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 4
239000000463 material Substances 0.000 description 4
229910052751 metal Inorganic materials 0.000 description 4
239000002184 metal Substances 0.000 description 4
SIMWTRCFFSTNMG-AWEZNQCLSA-N n-[[(5s)-3-[3-fluoro-4-[4-(2-hydroxyacetyl)piperazin-1-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCN(C(=O)CO)CC1 SIMWTRCFFSTNMG-AWEZNQCLSA-N 0.000 description 4
239000003921 oil Substances 0.000 description 4
238000005498 polishing Methods 0.000 description 4
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 4
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 4
229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
229940069328 povidone Drugs 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
238000003825 pressing Methods 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
239000000454 talc Substances 0.000 description 4
229910052623 talc Inorganic materials 0.000 description 4
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
238000001816 cooling Methods 0.000 description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
238000007873 sieving Methods 0.000 description 3
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
238000009472 formulation Methods 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000000047 product Substances 0.000 description 2
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
238000005086 pumping Methods 0.000 description 2
239000012265 solid product Substances 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
-1 3-fluoro-4-(4-morpholinyl)phenyl Chemical group 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
238000009835 boiling Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
238000004821 distillation Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
229940071676 hydroxypropylcellulose Drugs 0.000 description 1
230000003993 interaction Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
238000005192 partition Methods 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
238000000634 powder X-ray diffraction Methods 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000009492 tablet coating Methods 0.000 description 1
239000002700 tablet coating Substances 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
239000008096 xylene Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Infusion, Injection, And Reservoir Apparatuses (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

UA2002108322A 2000-03-22 2001-03-15 Compressed tablet of linezolide UA77654C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US19096900P	2000-03-22	2000-03-22
PCT/US2001/005812 WO2001070225A2 (en)	2000-03-22	2001-03-15	Oxazolidinone tablet formulation

Publications (1)

Publication Number	Publication Date
UA77654C2 true UA77654C2 (en)	2007-01-15

Family

ID=22703542

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2002108322A UA77654C2 (en)	2000-03-22	2001-03-15	Compressed tablet of linezolide

Country Status (33)

Country	Link
EP (1)	EP1265608B1 (de)
JP (1)	JP2003527424A (de)
KR (2)	KR20070094673A (de)
CN (1)	CN1208058C (de)
AR (1)	AR033357A1 (de)
AT (1)	ATE412413T1 (de)
AU (2)	AU2001243243B2 (de)
BG (1)	BG107117A (de)
BR (1)	BR0108846A (de)
CA (1)	CA2400118A1 (de)
CZ (1)	CZ20023133A3 (de)
DE (1)	DE60136341D1 (de)
DK (1)	DK1265608T3 (de)
EA (1)	EA006772B1 (de)
EC (1)	ECSP013979A (de)
ES (1)	ES2312422T3 (de)
HK (1)	HK1054325B (de)
HR (1)	HRP20020765A2 (de)
HU (1)	HUP0300378A3 (de)
IL (1)	IL151788A0 (de)
MX (1)	MXPA02009316A (de)
MY (1)	MY136370A (de)
NO (1)	NO20024505D0 (de)
NZ (1)	NZ521525A (de)
PE (2)	PE20011126A1 (de)
PL (1)	PL201686B1 (de)
PT (1)	PT1265608E (de)
SK (1)	SK12092002A3 (de)
TW (1)	TWI293028B (de)
UA (1)	UA77654C2 (de)
WO (1)	WO2001070225A2 (de)
YU (1)	YU69802A (de)
ZA (1)	ZA200207073B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0209265D0 (en)	2002-04-23	2002-06-05	Novartis Ag	Organic compounds
DK1749517T3 (da) *	2005-07-20	2008-11-03	Teva Pharma	Stabil farmaceutiske sammensætning af linezolid form IV
WO2010026597A1 (en) *	2008-09-02	2010-03-11	Hetero Research Foundation	Oral dosage forms of linezolid and processes for their preparation
EA027791B1 (ru) *	2010-11-24	2017-09-29	Мелинта Терапьютикс, Инк.	Фармацевтические композиции
WO2013088389A1 (en) *	2011-12-14	2013-06-20	Alembic Pharmaceuticals Limited	Linezolid premix
CN103505459B (zh) *	2012-06-20	2016-02-24	北京万生药业有限责任公司	利奈唑胺药物组合物
CN104622831B (zh) *	2013-11-06	2018-06-22	江苏豪森药业集团有限公司	一种口服片剂及其制备方法
NZ735973A (en)	2015-04-01	2023-06-30	Akebia Therapeutics Inc	Compositions and methods for treating anemia
CN106727396A (zh) *	2016-11-22	2017-05-31	湖北广济药业股份有限公司	一种ⅱ晶型利奈唑胺片及其制备方法
CN109481412A (zh) *	2018-08-17	2019-03-19	扬子江药业集团北京海燕药业有限公司	一种ii晶型利奈唑胺片及其制备工艺
WO2021216530A1 (en)	2020-04-20	2021-10-28	Akebia Therapeutics, Inc.	Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3993767A (en) *	1975-11-18	1976-11-23	A. H. Robins Company, Incorporated	Compositions to suppress gastric bleeding in indomethacin and phenylbutazone therapy
AUPP437698A0 (en) *	1998-06-30	1998-07-23	Baumgart, Karl	Methods for treatment of coronary, carotid and other vascular disease
EP1181288B1 (de) *	1999-05-27	2003-07-30	PHARMACIA & UPJOHN COMPANY	Bizyklische oxazolidinone als antibakterielle mittel

2001
- 2001-03-15 EP EP01916186A patent/EP1265608B1/de not_active Revoked
- 2001-03-15 DK DK01916186T patent/DK1265608T3/da active
- 2001-03-15 PL PL366067A patent/PL201686B1/pl unknown
- 2001-03-15 AU AU2001243243A patent/AU2001243243B2/en not_active Ceased
- 2001-03-15 MX MXPA02009316A patent/MXPA02009316A/es not_active Application Discontinuation
- 2001-03-15 NZ NZ521525A patent/NZ521525A/en unknown
- 2001-03-15 IL IL15178801A patent/IL151788A0/xx unknown
- 2001-03-15 KR KR1020077020576A patent/KR20070094673A/ko not_active Ceased
- 2001-03-15 JP JP2001568423A patent/JP2003527424A/ja not_active Ceased
- 2001-03-15 CA CA002400118A patent/CA2400118A1/en not_active Abandoned
- 2001-03-15 HK HK03106507.0A patent/HK1054325B/zh not_active IP Right Cessation
- 2001-03-15 UA UA2002108322A patent/UA77654C2/uk unknown
- 2001-03-15 SK SK1209-2002A patent/SK12092002A3/sk unknown
- 2001-03-15 AU AU4324301A patent/AU4324301A/xx active Pending
- 2001-03-15 EA EA200201006A patent/EA006772B1/ru not_active IP Right Cessation
- 2001-03-15 KR KR1020027012465A patent/KR100786410B1/ko not_active Expired - Fee Related
- 2001-03-15 CN CNB018064698A patent/CN1208058C/zh not_active Expired - Fee Related
- 2001-03-15 AT AT01916186T patent/ATE412413T1/de not_active IP Right Cessation
- 2001-03-15 BR BR0108846-7A patent/BR0108846A/pt not_active IP Right Cessation
- 2001-03-15 DE DE60136341T patent/DE60136341D1/de not_active Expired - Fee Related
- 2001-03-15 YU YU69802A patent/YU69802A/sh unknown
- 2001-03-15 CZ CZ20023133A patent/CZ20023133A3/cs unknown
- 2001-03-15 ES ES01916186T patent/ES2312422T3/es not_active Expired - Lifetime
- 2001-03-15 HU HU0300378A patent/HUP0300378A3/hu unknown
- 2001-03-15 HR HR20020765A patent/HRP20020765A2/hr not_active Application Discontinuation
- 2001-03-15 WO PCT/US2001/005812 patent/WO2001070225A2/en not_active Ceased
- 2001-03-15 PT PT01916186T patent/PT1265608E/pt unknown
- 2001-03-20 MY MYPI20011303A patent/MY136370A/en unknown
- 2001-03-22 EC EC2001003979A patent/ECSP013979A/es unknown
- 2001-03-22 PE PE2001000273A patent/PE20011126A1/es not_active Application Discontinuation
- 2001-03-22 TW TW090106735A patent/TWI293028B/zh active
- 2001-03-22 AR ARP010101348A patent/AR033357A1/es unknown
- 2001-05-15 PE PE2001000437U patent/PE20020499Z/es not_active IP Right Cessation
2002
- 2002-09-03 ZA ZA200207073A patent/ZA200207073B/en unknown
- 2002-09-18 BG BG107117A patent/BG107117A/bg unknown
- 2002-09-20 NO NO20024505A patent/NO20024505D0/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
AU4324301A (en)	2001-10-03
DK1265608T3 (da)	2008-12-08
NO20024505L (no)	2002-09-20
MY136370A (en)	2008-09-30
PE20020499Z (es)	2002-07-12
PL201686B1 (pl)	2009-04-30
ECSP013979A (es)	2002-01-25
KR100786410B1 (ko)	2007-12-17
BR0108846A (pt)	2003-05-06
SK12092002A3 (sk)	2002-12-03
HUP0300378A3 (en)	2004-11-29
HK1054325B (zh)	2006-01-13
EP1265608A2 (de)	2002-12-18
DE60136341D1 (de)	2008-12-11
PT1265608E (pt)	2008-12-15
CN1418097A (zh)	2003-05-14
ES2312422T3 (es)	2009-03-01
HUP0300378A2 (hu)	2003-06-28
BG107117A (bg)	2003-05-30
WO2001070225A2 (en)	2001-09-27
YU69802A (sh)	2005-11-28
TWI293028B (en)	2008-02-01
HRP20020765A2 (en)	2003-12-31
ZA200207073B (en)	2003-12-03
CZ20023133A3 (cs)	2003-01-15
EA006772B1 (ru)	2006-04-28
WO2001070225A3 (en)	2001-12-13
CN1208058C (zh)	2005-06-29
ATE412413T1 (de)	2008-11-15
AU2001243243B2 (en)	2004-10-14
NO20024505D0 (no)	2002-09-20
AR033357A1 (es)	2003-12-17
MXPA02009316A (es)	2004-04-05
PE20011126A1 (es)	2001-10-31
KR20070094673A (ko)	2007-09-20
NZ521525A (en)	2004-02-27
EA200201006A1 (ru)	2003-02-27
HK1054325A1 (zh)	2003-11-28
EP1265608B1 (de)	2008-10-29
KR20020083185A (ko)	2002-11-01
IL151788A0 (en)	2003-04-10
CA2400118A1 (en)	2001-09-27
PL366067A1 (en)	2005-01-24
JP2003527424A (ja)	2003-09-16

Publication	Publication Date	Title
JP2020143069A (ja)	2020-09-10	抗癌性組成物
IE57326B1 (en)	1992-07-29	Salts of omeprazole
MD3226842T2 (ro)	2021-03-31	Compoziții anticancer
CN105073783A (zh)	2015-11-18	具有增强的性能和改善的加工性的药物组合物
US6514529B2 (en)	2003-02-04	Oxazolidinone tablet formulation
EA039654B1 (ru)	2022-02-22	Кристаллические твердые формы солей n-{4-[(6,7-диметоксихинолин-4-ил)окси]фенил}-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, способы получения и методы использования
WO2016116077A1 (en)	2016-07-28	Polymer-stabilized amorphous forms of vortioxetine
KR100786410B1 (ko)	2007-12-17	옥사졸리디논 배합 정제
AU2001243243A1 (en)	2001-12-13	Oxazolidinone tablet formulation
AU2014362999B2 (en)	2017-10-12	Pharmaceutical dosage forms
EP3630069A1 (de)	2020-04-08	Amorphe formen von obeticholsäure
CA3087392A1 (en)	2021-01-16	Crystalline forms of niraparib tosylate
WO2010125572A1 (en)	2010-11-04	Compressed tablets and capsules containing efavirenz
WO2022003643A1 (en)	2022-01-06	Stable solid formulation of azilsartan kamedoxomil, or azilsartan or pharmaceutically acceptable salts thereof
JP7798890B2 (ja)	2026-01-14	非晶質固体分散体
CA3018321A1 (en)	2019-03-25	Novel crystalline form of eluxadoline
RU2690491C2 (ru)	2019-06-04	Твердофазный линезолидсодержащий препарат
WO2016165676A1 (en)	2016-10-20	Amorphous forms of vemurafenib
CN115960135A (zh)	2023-04-14	抗组胺类化合物及其制备方法和用途
WO2017020878A1 (en)	2017-02-09	Solid forms of amorphous dolutegravir
WO2016206660A1 (en)	2016-12-29	Solid forms of amorphous canagliflozin
FR2919864A1 (fr)	2009-02-13	Le solvate de 1,4-dioxane de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
WO2009050353A1 (fr)	2009-04-23	Le solvate de 3-méthylbutan-1-ol de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant